BeyondSpring  logo
BeyondSpring BYSI
$ 1.34 -0.74%

Quarterly report 2025-Q3
added 02-21-2026

report update icon

BeyondSpring Net Debt 2011-2026 | BYSI

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt BeyondSpring

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- -107 M -34 M - - -11.5 M -10.8 M -392 K - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-392 K -107 M -32.6 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
-47.4 M $ 2.08 -14.4 % $ 214 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
Altimmune Altimmune
ALT
-35.2 M $ 4.2 -2.67 % $ 298 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
-311 M $ 20.24 -3.44 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.8 1.87 % $ 4.36 M chinaChina
Aprea Therapeutics Aprea Therapeutics
APRE
-130 M $ 0.88 -3.72 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
-3.28 M $ 7.2 -1.64 % $ 1.99 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
-26 M $ 4.1 2.37 % $ 356 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-208 M $ 8.35 1.46 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
136 M $ 6.37 -2.75 % $ 1.54 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
argenx SE argenx SE
ARGX
-89.9 M $ 756.71 -1.33 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
54.6 M $ 10.91 1.58 % $ 394 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
65.3 M $ 25.33 -6.1 % $ 3.22 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Artelo Biosciences Artelo Biosciences
ARTL
-531 K $ 1.15 -3.36 % $ 2.32 M usaUSA
Arvinas Arvinas
ARVN
-141 M $ 12.97 -2.3 % $ 920 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
-115 M $ 61.74 -2.42 % $ 8.26 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 231.56 -0.83 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.39 -1.63 % $ 8.16 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
-72.3 M $ 1.17 -0.85 % $ 35.2 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
-39.6 M $ 4.39 -0.9 % $ 553 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
31.1 M $ 5.01 -7.47 % $ 37.5 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
-26.8 M $ 14.14 -0.21 % $ 1.9 B canadaCanada
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.68 -1.75 % $ 429 M britainBritain
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-63.1 M $ 4.69 0.21 % $ 395 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
-22.2 M $ 4.54 2.44 % $ 387 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Axon Enterprise Axon Enterprise
AXON
-404 M $ 570.5 5.18 % $ 43.2 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-205 M $ 162.28 -0.98 % $ 8.07 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.56 -0.58 % $ 16.1 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA